These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 9225961)

  • 1. Chimeric T-cell receptors: highly specific tools to target cytotoxic T-lymphocytes to tumour cells.
    Abken H; Hombach A; Heuser C; Sircar R; Pohl C; Reinhold U
    Cancer Treat Rev; 1997 Mar; 23(2):97-112. PubMed ID: 9225961
    [No Abstract]   [Full Text] [Related]  

  • 2. Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology.
    Suzuki M; Curran KJ; Cheung NK
    Pediatr Blood Cancer; 2015 Aug; 62(8):1326-36. PubMed ID: 25832831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric T-cell receptors: new challenges for targeted immunotherapy in hematologic malignancies.
    Biagi E; Marin V; Giordano Attianese GM; Dander E; D'Amico G; Biondi A
    Haematologica; 2007 Mar; 92(3):381-8. PubMed ID: 17339188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring synthetic immunity: From boutique to global.
    Levine BL
    Hum Vaccin Immunother; 2017 Oct; 13(10):2204-2206. PubMed ID: 28945504
    [No Abstract]   [Full Text] [Related]  

  • 5. ImmTACs for targeted cancer therapy: Why, what, how, and which.
    Oates J; Hassan NJ; Jakobsen BK
    Mol Immunol; 2015 Oct; 67(2 Pt A):67-74. PubMed ID: 25708206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric Antigen Receptor T-Cell Therapies Advancing.
    Brower V
    J Natl Cancer Inst; 2016 Nov; 108(11):. PubMed ID: 27920051
    [No Abstract]   [Full Text] [Related]  

  • 7. Grafting T cells with tumor specificity: the chimeric receptor strategy for use in immunotherapy of malignant diseases.
    Hombach A; Pohl C; Reinhold U; Abken H
    Hybridoma; 1999 Feb; 18(1):57-61. PubMed ID: 10211789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional design of chimeric T-cell antigen receptors for adoptive immunotherapy of cancer: architecture and outcomes.
    Shirasu N; Kuroki M
    Anticancer Res; 2012 Jun; 32(6):2377-83. PubMed ID: 22641678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric antigen receptors in cancer immuno-gene therapy: current status and future directions.
    Chicaybam L; Sodré AL; Bonamino M
    Int Rev Immunol; 2011; 30(5-6):294-311. PubMed ID: 22053970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CAR T-cell Therapy: A New Era in Cancer Immunotherapy.
    Miliotou AN; Papadopoulou LC
    Curr Pharm Biotechnol; 2018; 19(1):5-18. PubMed ID: 29667553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From the mouse cage to human therapy: a personal perspective of the emergence of T-bodies/chimeric antigen receptor T cells.
    Eshhar Z
    Hum Gene Ther; 2014 Sep; 25(9):773-8. PubMed ID: 25244568
    [No Abstract]   [Full Text] [Related]  

  • 12. Anti-MUC1 nanobody can redirect T-body cytotoxic effector function.
    Bakhtiari SH; Rahbarizadeh F; Hasannia S; Ahmadvand D; Iri-Sofla FJ; Rasaee MJ
    Hybridoma (Larchmt); 2009 Apr; 28(2):85-92. PubMed ID: 19249993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating the skin in patients undergoing chimeric antigen receptor modified T-cell therapy.
    Rubin CB; Elenitsas R; Taylor L; Lacey SF; Kulikovskaya I; Gupta M; Melenhorst JJ; Loren A; Frey N; June CH; Porter D; Rosenbach M
    J Am Acad Dermatol; 2016 Nov; 75(5):1054-1057. PubMed ID: 27745631
    [No Abstract]   [Full Text] [Related]  

  • 14. Chimeric antigen receptor T-cell therapy to target hematologic malignancies.
    Kenderian SS; Ruella M; Gill S; Kalos M
    Cancer Res; 2014 Nov; 74(22):6383-9. PubMed ID: 25371415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CARTs for Solid Tumors: Feasible or Infeasible?
    Li W; Song X; Jin Y; Li F; Yu H; Cao C; Jiang Q
    Oncol Res Treat; 2017; 40(9):540-546. PubMed ID: 28813706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric antigen receptor T cells for the treatment of cancer and the future of preclinical models for predicting their toxicities.
    Wegner A
    Immunotherapy; 2017 Jun; 9(8):669-680. PubMed ID: 28653571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric Antigen Receptor T Cell Therapy in Hematology.
    Ataca P; Arslan Ö
    Turk J Haematol; 2015 Dec; 32(4):285-94. PubMed ID: 26377367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [T Lymphocytes with Modified Specificity in the Therapy of Malignant Diseases].
    Vdovin AS; Bykova NA; Efimov GA
    Mol Biol (Mosk); 2017; 51(6):1008-1023. PubMed ID: 29271964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Armed T cells with CAR for cancer immunotherapy.
    Wei YQ
    Sci China Life Sci; 2016 Apr; 59(4):331-2. PubMed ID: 27080712
    [No Abstract]   [Full Text] [Related]  

  • 20. Chimeric Antigen Receptor T Cell Based Immunotherapy for Cancer.
    Li F; Zhang T; Cao L; Zhang Y
    Curr Stem Cell Res Ther; 2018; 13(5):327-335. PubMed ID: 29676233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.